Better Health for All

Evotec's core business is the discovery and development of medicines for communicable and non-communicable diseases, aiming to improve quality of life and accessibility, with 33% of its pipeline targeting diabetes, cardiovascular disease, and cancer.

The company also develops biosimilars and a teratogenicity platform to enhance drug safety, and supports the development of next-generation tuberculosis drug combinations. There is no evidence of revenue from products with negative health impacts. In 2024, Evotec's R&D expenditures were €50.8 million, and its 2023 revenue was €781.4 million, indicating that 6.5% of revenue was allocated to R&D. The company has pandemic virus projects for SARS-CoV-2 and Nipah virus, and a pandemic preparedness and rapid response network (PRROTECT) initiative. In 2023, Evotec implemented a mental health campaign.

Fair Money & Economic Opportunity

Evotec SE is a drug discovery and development company, not a financial institution.

The company's core business does not involve lending, insuring, moving, or storing money for consumers. Therefore, all KPIs related to fair money and economic opportunity, which are designed for financial services, are not applicable to Evotec SE. The evidence provided focuses on the company's efforts in drug discovery, manufacturing cost efficiency for biotherapeutics, global access to medicines, internal ESG activities, and data platforms for research, none of which directly relate to consumer financial products or services.

Fair Pay & Worker Respect

In 2023, 65.9% of employees in Austria, France, Germany, and Italy were covered by collective bargaining agreements.

The rate of recordable work-related injuries (TRIR) was 0.22 per 200,000 hours in 2024, with no fatalities reported in 2023 or 2024. The median gender pay gap for Evotec (UK) Ltd was 13.1% in 2024, meaning women earned 86.9% of men's median pay, while Aptuit (Oxford) Ltd had a median gender pay gap of 4.6% in 2024. The median gender bonus gap for Evotec (UK) Ltd was 15.4% in 2024. The employee engagement score from a 2024 pulse survey was 73%, with a baseline of 40% in 2025 for an LTI plan target. The workforce attrition rate was 12.0% in 2023. The company received 29 whistleblower notifications in 2023 and 9 in 2022. In 2023, 491 employees were temporary, representing 9.5% of the total workforce of 5,150.

Fair Trade & Ethical Sourcing

Evotec SE reported no substantiated incidents of forced or child labor in the last three years, and states it is not aware of any risks relating to such incidents in its operations.

The company's Supplier Code of Conduct (SCoC) is applicable to all suppliers, regardless of size or geographical location, and suppliers are contractually committed to it, with an expectation to implement these standards with their own suppliers and subcontractors. However, the value chain analysis remains high-level and qualitative, focusing primarily on first-tier suppliers, meaning not all workers in the value chain can be fully assessed. For identified violations, whistleblowers receive feedback within three months.

Honest & Fair Business

Evotec SE has a formal whistleblower platform, EVOwhistle, which received 22 reports in 2024.

Its subsidiary, Aptuit, has a formal whistleblowing policy compliant with Italian and EU law, detailing encrypted reporting channels, confidentiality, and protection against retaliation, covering a broad range of stakeholders. For Aptuit, receipt of reports is confirmed within 7 days, and notification of response to verification activities is provided within 3 months. Evotec's consolidated and separate financial statements for 2024 were audited by BDO AG Wirtschaftsprüfungsgesellschaft. The company has a Code of Ethics and Business Conduct, revised in 2023, addressing anti-corruption and bribery, and conducts regular mandatory electronic compliance training.

Kind to Animals

Evotec uses a broad range of non-animal methods, including in silico tools, integrated AI/ML approaches, and New Approach Methodologies (NAMs) such as human-based in vitro systems, organoids, and iPSC-derived assays, which routinely replace animal experimentation.

For drug-induced liver injury (DILI), their new prediction platform achieved 86% predictive accuracy, compared to 50% with animal models. All six relevant research sites were accredited by AAALAC International by the end of 2020, with re-accreditations occurring every three years, including Hamburg and Verona in 2021, and Göttingen and Alderley Park in 2022. The company monitors 5,660 suppliers for ESG criteria and conducts in-depth assessments for 238 out of 475 'A' suppliers. Evotec's Global Animal Welfare Policy, updated in 2019 and reviewed annually, commits to the 3Rs principles (Replacement, Reduction, Refinement) and requires regulatory approval for all animal experiments based on European and national legislation. The company aims to reduce animal testing in pharmaceutical R&D and monitors a 'Right First Time' (RFT) rate, which averaged 95.55% in 2023, to avoid unnecessary animal testing. However, the number of animals used each year depends on variables, and specific volume data is not provided, though the company aims for the average number of animals per project to decrease. Less than 1% of R&D spending supports the development of non-animal methods. Evotec collaborates with industry, academia, and federal agencies through ICCVAM to accelerate validation and adoption of NAMs and is committed to working with partners, regulatory bodies, and stakeholders to embrace the concepts outlined in the FDA Road Map. Evotec's approach aligns with the FDA's roadmap to reduce animal testing and the FDA Modernization Act 2.0 passed by Congress in 2022, and the company welcomes the FDA's roadmap.

Planet-Friendly Business

The provided articles do not contain specific quantitative data or concrete facts for any of the Planet-Friendly Business KPIs. The sustainability report summary explicitly states that no quantitative data is provided for metrics such as Scope 1, 2, or 3 emissions, SBTi-aligned targets, renewable energy, water use, green buildings, waste diversion, EU Taxonomy alignment, lifecycle impact analysis, recycled/virgin ratios, carbon offset quality, climate-positive initiatives, supply chain climate transparency, supplier SBTi targets, biodiversity efforts, deforestation policy implementation, environmental compliance violations, environmental impact assessments, net-zero target year, TCFD alignment, climate scenario analysis, stranded assets transparency, water from stressed basins, packaging CO2 reduction, climate justice initiatives, or just transition programs.

Therefore, all KPIs must be omitted due to a lack of evidence.

Safe & Smart Tech

Evotec uses at least 128-bit TLS encryption for email and web traffic.

The company retains data only as long as necessary for stated purposes. Users can manage communication preferences and unsubscribe from marketing emails. Evotec states compliance with GDPR, CCPA, and other relevant regulations. A criminal cyber-attack occurred on April 6, 2023, impacting productivity throughout Q2 2023, with one-off costs of approximately €25m in Q2 2023. The integrity of scientific data remained unaffected by this attack.

Zero Waste & Sustainable Products

In 2022, Evotec SE achieved a waste diversion rate of 85.27%, diverting 3,068 tonnes of waste from landfill through recycling and incineration, while 530 tonnes were sent to landfill.

This represents an increase from 2021, when the diversion rate was 77.32% (1,447 tonnes recycled, 2,149 tonnes incinerated, 1,055 tonnes to landfill). The company reported no significant fines or non-monetary sanctions related to waste disposal violations and stated compliance with all applicable laws and regulations.